Live Breaking News & Updates on Corneal Endothelial Cell Substitute

Stay updated with breaking news from Corneal endothelial cell substitute. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001

Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Shin Hatou , Department Of Ophthalmology , Icellusion Inc , Keio University School Of Medicine , Drug Administration , Drug Designation , Orphan Drug Designation , Search Orphan Drug Designations , Corneal Endothelial Cell Substitute , Keio University School , More Smiles ,

Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round

Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hiroaki Kobayashi , Fosun Pharma , Shin Hatou , Norio Takada , Junichi Imoto , Yoshiharu Asai , Shigeto Shimmura , Keio University Hospital , Gemseki Inc , Innovation Fund , Head Office , Venture Capital Co Ltd , Mirai Creation Fund , Axil Capital Partners , Capital Co Ltd , Icellusion Inc , Co Ltd , Asset Management Co Ltd , Fujita Health University , Venture Growth Investments Co Ltd , Keio University , Seriesc Round , More Smiles , Greater China , First In Human Study , Chief Venture Capitalist ,

Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy

Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , New Jersey , Minari Allendale , Hidehito Takahashi , Noriko Takada , Hiroto Bando , Shin Hatou , Minaris Regenerative Medicine , Keio University School Of Medicine , World Health Organization , Icellusion Inc , Un Sustainable Development Goals , Showa Denko Materials Co Ltd , Keio University Hospital , Department Of Ophthalmology , Corneal Endothelial Cell Substitute , Corneal Endothelial Cell Regenerative , Progenitor Cell Therapy , Hitachi Chemical , Development Goals , Investigator Initiated Study , Keio University , Bullous Keratopathy , Corneal Endothelial , Showa Denko Materials , Keio University School ,

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 f

Celregen Obtains the Exclusive Rights to Develop, Manufacturing and Commercialize CLS001 in Greater China Region; Cellusion Retains Other Regional Rights.The Deal is Worth up to over $100 Million, including Upfront, Development and Sales Milestone Payments, and Tiered Royalties.TOKYO & HANGZHOU, China & SHANGHAI (B. ....

United States , Hong Kong , Wen Deyong , Joji Hayashida , Jialei Ma , Shin Hatou , Fosun Pharma , Cui Zhiping , Keio University School Of Medicine , Sinopharm Co Ltd , Shanghai Fosun Pharmaceutical Group Co Ltd , Fosun Health Capital , Drug Fund , Hangzhou Celregen Therapeutics Ltd , Icellusion Inc , Drug Fund Of Fosun Health Capital , Fosun New Drug Fund , Keio University Hospital , Department Of Ophthalmology , Celregen Obtains , Exclusive Rights , Greater China Region , Sales Milestone Payments , Corneal Endothelial Cell Substitute , Hangzhou Celregen Therapeutics , Shanghai Fosun Pharmaceutical ,

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region - read this article along with other careers information, tips and advice on BioSpace ....

United States , Hong Kong , Wen Deyong , Shin Hatou , Fosun Pharma , Cui Zhiping , Keio University School Of Medicine , Sinopharm Co Ltd , Shanghai Fosun Pharmaceutical Group Co Ltd , Fosun Health Capital , Drug Fund , Hangzhou Celregen Therapeutics Ltd , Icellusion Inc , Drug Fund Of Fosun Health Capital , Fosun New Drug Fund , Keio University Hospital , Department Of Ophthalmology , Corneal Endothelial Cell Substitute , Hangzhou Celregen Therapeutics , Shanghai Fosun Pharmaceutical , New Drug Fund , New Drug , Greater China , Mainland China , Fosun Global Partner , Chief Consultant ,